Pharmaceutical Manufacturing - Study reveals how manufacturing methods affect herbal medicine potency
View as a Web Page
News Medical
 
  Pharmaceutical Manufacturing Pharmaceutical Manufacturing logo  
  The latest pharmaceutical manufacturing news from News Medical  
 

How oxygen enhances safety in Pharmaceutical ProductionHow oxygen enhances safety in Pharmaceutical Production

Maintaining safe oxygen levels is critical in pharmaceutical manufacturing, where volatile vapours and specialty chemicals create potentially hazardous conditions. This application note explores how continuous oxygen monitoring supports nitrogen purging processes, helping manufacturers improve safety, maintain compliance, and optimize production efficiency.
Download and explore practical solutions for safer, more efficient operations.

Download the App Note
 
   Study reveals how manufacturing methods affect herbal medicine potencyStudy reveals how manufacturing methods affect herbal medicine potency
 
In a study published in Signal Transduction and Targeted Therapy, the researchers used MIR2911, a plant microRNA enriched in honeysuckle, as a proof-of-concept example.
 
   SwRI advances safer manufacturing of nerve agent antidotesSwRI advances safer manufacturing of nerve agent antidotes
 
Southwest Research Institute (SwRI) continues to expand its unique drug synthesis capabilities and expertise to advance the scalable manufacturing of safer antidotes to combat exposure to organophosphorus nerve agents (OPNAs) and pesticides.
 
   Autolomous and Cellular Origins expand platform integration to deliver end-to-end cell therapy manufacturing orchestrationAutolomous and Cellular Origins expand platform integration to deliver end-to-end cell therapy manufacturing orchestration
 
Autolomous and Cellular Origins today announce end-to-end integration of their respective platforms, bringing full automation and digitization to the entire cell therapy manufacturing process.
 
   Cellares to expand automated manufacturing to gene-edited stem cell therapiesCellares to expand automated manufacturing to gene-edited stem cell therapies
 
Cellares, the first Integrated Development and Manufacturing Organization (IDMO), today announced a collaboration with the Stanford Center for Definitive and Curative Medicine (CDCM) and Stanford Innovative Medicines Accelerator (IMA) to automate manufacturing and release testing for gene-edited hematopoietic stem cell (HSC) therapies, expanding the application of Cellares' automation platforms beyond T cell therapies into a new cell modality.
 
 

How would you rate today's newsletter?

 
             
 
 
Google News Icon Stay updated with the latest in health and medical news! Follow News‑Medical.net on Google News for real‑time updates. Click here to follow us now.
 
Facebook X Instagram LinkedIn Vimeo
Why did you receive this email?
You are receiving this email because you subscribed to updates from AZoNetwork UK Ltd. on one of our websites and requested to be notified of additional information.

Unsubscribe or Update Notification Preferences

Contact | About | Privacy Policy

- - - - - -

Registered Address:
AZoNetwork UK Ltd., NEO, 9 Charlotte St, Manchester, M1 4ET, UK

Manchester | Sydney | Boston

Copyright © 2000-2026